Disclosure

Disclosure. Commodity Trader Disclosure Acknowledgement

997 views • 85 slides

Disclosure

Disclosure. None of the speakers, planners, nor anyone in control of content for today’s Medical Home Demonstration Project Learning Session has any relevant financial relationships to disclose. . Medical Home Demonstration. How do you define “medical home”?

336 views • 16 slides

Disclosure

Understanding and optimizing  pharmacologic agents used in the management of Pulmonary Hypertension. Dr. Christopher J Arendt, PharmD , RPh Assistant Professor of Pharmacy Mayo Clinic College of Medicine Rochester, Minnesota. Disclosure. Nothing to disclose No financial interests.

494 views • 25 slides

Disclosure

Prognostic Value of Programmed Electrical Stimulation Among Implantable Cardioverter -Defibrillator Recipients Real-World Data from the Israeli National ICD Registry.

414 views • 23 slides

Disclosure

409 views • 29 slides

Disclosure

Improving health care transitions from pediatric to adult care settings: the experience of the New Hampshire health care transition learning collaborative W. Carl Cooley Co-Director, Got Transition – the National Health Care Transition Center

750 views • 50 slides

Disclosure

Disclosure. ?. Questions & Answers. 1 + 1 = 2. A systematic approach. Why would you disclose? What will you disclose? When To whom How. Student’s experiences. I don’t think I’ll ever do that again… because of my last place I don’t know if I’ll ever be as open ever again to be honest.’.

263 views • 7 slides

Disclosure

The Implications of the American Academy of Pediatrics Policy Statement on Cholesterol in Childhood. Disclosure.

596 views • 33 slides

Disclosure

Disclosure. Neither I nor any member of my immediate family has a financial relationship or interest with any proprietary entity producing health care goods or services related to the content of this CME activity.

853 views • 68 slides

Disclosure

How Can We Use Advanced Neuroimaging in the ED to Optimize Treatment Options for Acute Stroke Patients?.

478 views • 24 slides

Disclosure

2 or 3 Year DFS is an Appropriate Primary Endpoint in Stage III Adjuvant Colon Cancer Trials with Fluoropyrimidines with or without Oxaliplatin or Irinotecan.

441 views • 28 slides

Disclosure

Disclosure. This program was developed by the University of Calgary and University of Sherbrooke through an educational grant from Pfizer Canada Inc. Disclosure of potential conflicts of interest of (your name): Indicate research grants received

620 views • 35 slides

Disclosure:

Interventional Radiology Percutaneous Catheters Indications, Techniques & Management By Dr. Steve J. Lengle, MD. Disclosure: Dr. Lengle has no financial interest in any of the products or manufacturers mentioned. Interventional Radiology.

991 views • 75 slides

Disclosure

Disclosure. Dr. Bhatt has received honoraria from: Astra Zeneca, Bristol-Myers Squibb, Eli Lilly, Millennium, Schering Plough, sanofi aventis, The Medicines Company. This presentation discusses off-label uses of clopidogrel. This study was funded by sanofi aventis and Bristol-Myers Squibb.

442 views • 30 slides

Disclosure

The Pharmacy Practice Model: Where are we going and how will we get there? John B. Hertig, PharmD, MS Medication Safety Project Manager Assistant Clinical Professor of Pharmacy Practice Center for Medication Safety Advancement Purdue University College of Pharmacy Indianapolis, IN. Disclosure.

706 views • 41 slides

Disclosure

Key Insights From the 2013 American Academy of Neurology Meeting: Translating Clinical Data Into Clinical Practice. Disclosure. Disclaimer. Program Goals. Combination Therapy. Relapse. Injectable Therapy. Balancing Safety and Efficacy. Oral Disease-Modifying Therapies. Fingolimod.

351 views • 22 slides

Disclosure

Disclosure In relation to this presentation, I declare the following, real or perceived conflicts of interest: - - -.

182 views • 2 slides

Why Need To Negotiate a Franchise With Franchise Disclosure Document

Be sure your attorney carefully reviews this section and that you see your obligations and rights for negotiating a franchise. These stand for some of the more notable examples of subdivisions in a franchise arrangement, which you and your attorney may wish to negotiating a franchise. A Franchise Disclosure Document is a complicated document and by design is favoured the franchisor. You must realize that other franchises might get upset and feel that they did not make as good a sight if the Franchisor makes special deals for some and not others.

98 views • 4 slides

Make Up the Heart of Franchise Disclosure Document

The heart and soul of the disclosure slice of the Franchise Disclosure Document (FDD) --and certainly its very purpose - is set forth in the Items.

117 views • 5 slides

Disclosure

“Starting from scratch” The South Australian Medicines Evaluation Panel Nadine Hillock Catherine Hill. Disclosure. Nadine Hillock: I have no financial or non-financial conflicts of interest to disclose in relation to this presentation. Catherine Hill:

406 views • 30 slides